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Experimental autoimmune encephalomyelitis (EAE)' is a paralytic and inflam-
matory disease ofthe central nervous system mediated by Th cells specific for my-
elin basic protein (BP) (1). The encephalitogenic epitope(s) ofBP differ among an-
imalstrainsand arerestricted by the availableMHC class II molecules, predominantly
I-A (2-5), and in one case, the B.10/PL mouse, by I-E (6). The major encephalito-
genic epitope for the Lewis rat is the 72-89 sequence of guinea pig (GP)- or rat
(Rt)-BP, restricted by I-A. T cell lines and clones selected with whole BP in vitro
from lymph nodes collected 9 d after immunization with GP-BP respond only to
the 72-89 determinant (7-9) and utilize preferentially the rat homologs ofthe mu-
rineVc12.VO8 gene combination in their TCR (10). Other determinants ofGP-BP
(i.e., the 44-68 sequence) maybeimmunogenicinthe absence oftheimmunodominant
72-89 epitope (11), however, and it has been unclear why BP-selected T cell lines
do not contain T cell specificities to epitopes other than the 72-89 sequence.
In this report, we have evaluated the T cell specificities present in lines selected
from lymph nodes of Lewis rats before and after recovery from EAE induced with
either GP- or Rt-BP. With both BPs, a second T cell specificity appeared later than
the primary72-89-specificresponseandpersisted in thelines. Evidence is presented
to show that the secondary GP-BP determinant, first detected 14 d after immuniza-
tion, was included in the 55-68 sequence and was restricted by I-A. T cells specific
for this determinant did not respond to the corresponding Rt-BP sequence, which
differs by three residues at positions 61-63, and were not encephalitogenic in spite
of their ability to transfer delayed-type hypersensitivity (0TH) reactions in vivo,
The secondary Rt-BP epitope was found in the 87-99 sequence and was restricted
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by I-E. Rat T cell lines and clones responsive to the 87-99 determinant were en-
cephalitogenic and also transferred DTH reactions, and active immunization with
the 87-99 peptide in CFA induced EAE. T cell clones specific for the 87-99 peptide
restricted by I-E utilized the same TCR Vat.Vf8 gene combination as clones specific
for the GP-BP 72-89 sequence restricted by I-A (8, 10). This is the first demonstra-
tion of I-E-restricted encephalitogenic T cells in Lewis rats. These results support
the conclusion that the I-E class II locus is involved in autoimmune diseases.
Materials and Methods
Rats.
￿
Lewis female rats, N8 wk old, were purchased from Harlan Spraque Dawley, Inc.,
Indianapolis, IN, and were housed and cared for in the Animal Resource Facility at the Port-
land Veterans Administration Medical Center.
Antigens.
￿
GP- and Rt-BP were prepared according to the method of Eylar et al. (12). Pro-
teolytic cleavage fragments ofGP-BP (kindly provided by Dr. C. H. J. Chou, EmoryUniver-
sity, Atlanta, GA) were obtained and purified to contain >95 17o of the desired peptide by
ion-exchange chromatography as described previously by Chou et al. (13). Myelin BP pep-
tides were synthesized by solid phase techniques (14) according to the sequences for GP- or
Rt-BP (15). All preparations were >95% pure as determined by HPLC and amino acid anal-
yses. The sequences of peptides used in this study are shown in Table I.
T Cell Lines and Clones.
￿
T cell lines were selected as described previously (1) from lymph
nodes of rats immunized either with GP- or Rt-BP, with peptides obtained by proteolysis
of GP-BP, or with synthetic peptides emulsified in CFA containing 400 Fog H37Ra (Difco
Laboratories Inc., Detroit, MI). T cell clones were isolated from the lines by the soft agar
technique described earlier (8). Designations given to T cell lines and clones are shown in
Table II. Activation of T cells was measured by [3H]Tdy uptake. 5 x 105 lymph node cells
or 2 x 104 line cells in the presence of 106 irradiated thymic accessory cells were incubated
with culture medium, antigens, and in some experiments with mAbs specific for I-A (OX-6)
or I-E (OX-17) in microtiter wells for 18 h before the addition of 0.5 p.Ci labeled thymidine.
The cell cultures were harvested onto glass fiber filters and counted by liquid scintillation
techniques. Mean cpm was calculated from triplicate cultures. SD from replicate cultures
varied <10% from the mean value.
Induction ofEAEand DTH.
￿
Active EAE was induced by injecting BP or peptide emulsified
with CFA. Each rat received a single dose of 100 pg antigen and 100 AgMycobacterium tubercu-
losis or M. butyricum. Passive EAE was induced by injecting intraperitoneally 6-10 x 106 T
line cells, which were activated with specific antigen presented by syngeneic thymic accessory
cellsfor 3 d. Clinical signs were monitored daily on a scaleof0 to 4: 0, no signs; 0.5, lethargy
and weight loss; 1, limp tail; 2, hind leg weakness; 3, hemiparalysis; 4, paralysis of front and
hind limbs/moribund condition. Brain and spinal cord tissues were collected within 4 d of
recovery from EAE or after30 d and evaluated for histological evidence ofEAE. DTH reac-
tions were measured by the ear swelling assay (16) 24 and 48 h after injection intradermally
of 20 Rg antigen.
7LR V Gene Expression.
￿
T cell RNA extracts were evaluated for the presence of specific
Vat and V/08 sequences using cDNA probes Va 510 and VS 510 (10). The Va 510 probe
is 135 by with Eco RI and Pst I restriction enzyme treatment, and the V/3 510 probe is 240 by
with Eco RI and Alu I treatment and includes 6 by of D region sequence. Northern blot
hybridizations were performed using 32P-labeled probes as described previously (10).
Results
Secondary T Cell Epitope of GP-BP.
￿
As we have shown previously, a GP-BP-specific
T cell line, GP-BP(d9), and the D9 clone selected from Lewis rat lymph nodes 9
d after immunization recognized only the encephalitogenic S72-89 peptide sequence,
and failed to respond to other epitopes present on GP-BP (Table III). The responseOFFNER ET AL.
TABLE I
BP Peptide Sequences
Peptide
￿
Single-letter amino acid sequence
357
GP-BP
44-68 FGSDRAAPKRGSGKDSHHAARTTHY
GP-BP
S39-54 SIGRFFGSDRAAPKRG
GP-BP
S55-74
￿
SGKDSH - -TRTTHYGSLPQK
Rt-BP
S55-74 (modified)
￿
SGKDSHHATRTTHYGSLPQK
GP-BP
S72-89
￿
PQKSQ--RTQDENPVVHF
Rt-BP
S72-89
￿
PQKSQ-- STQDENPVVHF
Rt-BP
S87-99
￿
VHFFKNIVTPRTP
Rt-BP
S88-99
￿
HFFKNIVTPRTP
Rt-BP
S90-99
￿
FKNIVTPRTP
Rt-BP
S91-99
￿
KNIVTPRTP
Numbering system conforms to the bovine BP numbering system of Eylar et al. (12). S indicates synthetic peptide.
to S72-89 of both the GP-BP(d9) line and the D9 clone was inhibited by the OX-6
mAb specific for I-A, but not by OX-17 specific for I-E (Table III).
We evaluated rats after recovery from EAE to determine if additional T cell
specificities were present in GP-BP-selected T cell lines. As shown in Table III, T
cell lines selected with whole GP-BP 28 d after immunization with GP-BP/CFA
responded not only to the S72-89 peptide (as expected), but also to the 44-68 frag-
ment of GP-BP Responses to other fragments ofGP-BPdid not persist during line
TABLE II
T Cell Line Designations
T cell line/clone Immunizing antigen Line initiation Selecting antigen Specificity
GP-BP(d9) GP-BP Day 9 GP-BP GP-BP S72-89
Clone D9 GP-BP Day 9 GP-BP GP-BP S72-89
GP-BP(d14-28) GP-BP Days 14-28 GP-BP GP-BP S72-89
GP-BP44-68 GP-BP Days 14-28 GP-BP 44-68 GP-BP 55-68
GP-BP(44-68) GP-BP 44-68 Day 12 GP-BP 44-68 GP-BP 55-68
Rt-BP(d9) Rt-BP Day 9 Rt-BP Rt-BP S72-89
Rt-BP(d20) Rt-BP Day 20 Rt-BP Rt-BP S72-89
Rt-BP87-99 Rt-BP Day 20 Rt-BP S87-99 Rt-BP S87-99
Rt-BP(87-99) Rt-BP S87-99 Day 12 Rt-BP S87-99 Rt-BP S87-99
Clones C-3,
C-6, and C-10 Rt-BP S87-99 Day 12 Rt-BP S87-99 Rt-BP S87-99358
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TABLE III
Specificity of GP-BP-specific T Cell Lines from Lewis Rats
before and after Recovery from GP-BP-induced EAE
20,000 T line cells or clones were stimulated for 3 d in the presence ofantigens
and 106 syngeneic thymic accessory cells. Proliferation was measured by uptake
of [3H]Tdy during the last 18 h of culture. mAbs specific for I-A or I-E were
added at the beginning of the culture period to establish MHC class II restric-
tion. Parentheses indicate percent inhibition. PPD, purified protein derivative
of M. tuberculosis.
selection. The responses to both S72-89 and 44-68 peptides were completely in-
hibited by OX-6 but not OX-17, indicating that both were restricted by I-A.
The T cell population specific for the GP-BP 44-68 determinant could be de-
tected in lymph node cell populations as early as 14 d after immunization with GP-
BP (Table IV). The 44-68-specific response persistedin four different GP-BP-selected
T cell lines produced from lymph nodes collected on days 14, 17, 24, and 28 after
immunization with GP-BP (Table IV), and was consistently 20-40% as large as the
response to the S72-89 epitope.
TABLE IV
Response to GP-BP 44-68 Fragment Remains Stable after
Appearing on Day 14 after Immunization
" Data represent percent .
Proliferation response
Stimulant
None
Proliferation
GP-BP(d9)
10t 1
response of T
D9 clone
cpm/1, 000
2 t0
cell line/clone :
GP-BP(d28)
6±1
GP-BP 153 t 2 110 1 5 228 1 18
Rt-BP 68 1 5 68 1 2 72 1 8
1-37 8 f 1 1 t 1 6 t 1
44-89 111 f 8 158 ± 12 158 t 15
44-68 10 t 1 1 f 0 58 1 4
+ OX-6 (a I-A) ND ND 4 ± 1 (100)
+ OX-17 (cr I-E) ND ND 59 t 5 (0)
S72-89 109 ± 9 167 ± 4 137 1 12
+ OX-6 (cx I-A) 10 ± 2 2 t 0 5 * 1 (100)
+ OX-17 (« I-E) 100 t 11 155 t 8 127 t 10 (8)
90-169 13 1 1 2 ± 1 7 t 1
PPD 9 t 1 1 t 0 5 t 1
Stimulant
Day
LN
9
Line
Day
LN
14
Line
cpm/1,
Day
LN
000 -
17
Line
Day
LN
background
24
Line
Day
LN
28
Line
44-68 0 0 17 24 12 35 10 18 4 52
S72-89 14 99 41 119 34 100 28 58 13 131
44-68/72-89
response" 0 0 41 20 35 35 36 31 31 40OFFNER ET AL .
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To enrich for 44-68-specific T cells, a line containing T cells of both 72-89 and
44-68 specificities was subselected by restimulating three times with a highly purified
44-68 fragment ofGP-BP (Table V) . This subline, designated GP-BP44-fib, respond-
ed selectively to the 44-68 fragment in the context of I-A, and retained responsive-
ness to the parent 44-89 fragment and to whole GP-BP However, the GP-BP44-68
subline did not respond either to the 72-89 peptide of GP-BP or to whole Rt-BP
(Table V) . A second T cell line specific for the 44-68 fragment ofGP-BP, designated
GP-BP(44-68), was selected from lymph nodes of Lewis rats immunized with the
44-68 fragment in CFA, using only the 44-68 peptide as antigen . This T cell line
was specific for the 44-68 fragment and was I-A restricted, recognized the parent
44-89 fragment and GP-BP, but failed to recognize either the GP-BP S72-89 pep-
tide or Rt-BP (Table V) .
To delineate further the T cell epitope involved, we stimulated the GP-BP(44-68)
line with synthetic peptides corresponding to sequences in GP- and Rt-BP (Table
V) . No stimulation was observed to the GP-BP S39-54 or S72-89 sequences, or to
the Rt-BP S55-74 sequence, which has a two-amino acid deletion (HA) relative
to theGP sequence at positions 61 and 62, and aT forA substitution at position 63
(see Table I) . However, a modified rat sequence with T at position 63 and theHA
insertion at positions 61 and 62 was partially stimulatory for the 44-68-specific T cells
(Table V) . Thus, the shortest sequence recognized by the T cells included residues
55-68 of GP-BP
Secondary TCell Epitope ofRt-BP .
￿
In a manner similar to that described for GP-
BP, we evaluated T cell responses in rats before and after recovery from Rt-BP-induced
EAE . Lewis rats were immunized for 9 or 20 d with Rt-BP in CFA, and T cell lines
TABLE V
Characterization of GP-BP 44-68-speck T Cell Lines
20,000 T line cells or clones were stimulated for 3 d in the presence of antigens
and 106 syngeneic thymic accessory cells . Proliferation was measured by uptake
of [3H]Tdy during the last 18 h of culture . mAbs specific for I-A or I-E were
added at the beginning of the culture period to establish MHC class II restric-
tion . Parentheses indicate percent inhibition .
Stimulant
Proliferation
GP-BP44-68
response ofT cell line :
GP-BP(44-68)
cpm/1, 000
None 12 t 2 15 t 4
GP-BP 215 f 20 124 t 6
Rt-BP 8 t 2 15 t 2
1-37 10 t 1 10 t 1
44-89 200 t 21 124 t 14
44-68 171 t 14 141 t 21
+ OX-6 (a I-A) 8 t 2 (100) 10 t 2 (l00)
+ OX-17 (a I-E) 166 t 12 (3) 134 f 9(6)
GP-BP S39-54 ND 12 t 1
Rt-BP S55-74 ND 12 t 0
Rt-BP S55-74 ND 60 t 3
S72-89 10 t 1 15 t 2
90-169 11 t 1 12 t 2360
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TABLE VI
Specificity of Rt-BP-speck T Cell Lines from Lewis Rats
before and after Recoveryfrom Rt-BP-induced EAE
20,000 T line cells or clones were stimulated for 3 d in the presence of antigens
and 106 syngeneic thymic accessory cells. Proliferation was measured by uptake
of [3H]Tdy during the last 18 h of culture. mAbs specific for I-A or I-E were
added at the beginning of the culture period to establish MHC class II restric-
tion. Parentheses indicate percent inhibition.
were selected from lymph nodes using whole Rt-BP As is shown in Table VI, Rt-
BP-specific T cell lines selected 9 d after immunization responded to Rt-BP and
to the immunodominant S72-89 peptide of Rt-BP, but not to the 44-68 or S87-99
sequences of BP Consistent with our previous results (9), the Rt-BP(d9) response
to S72-89 was inhibited by OX-6 but not OX-17 mAb, indicating restriction by I-A
MHC molecules.
In contrast to the Rt-BP(d9) T cell line, a second T cell line selected from recov-
ered rats 20 d afterimmunization, designated Rt-BP(d20), respondedalmost equally
to both the S72-89 and the S87-99 sequences of Rt-BP (Table VI). As expected,
the response of the Rt-BP(d20) line to S72-89 was I-A restricted. Surprisingly, the
response of this line to S87-99 was inhibited by OX-17 but not OX-6, indicating
that the S87-99-specific T cells were restricted by I-E (Table VI).
Three approaches were used to enrich for S87-99-specific T cells. First, an S87-99-
specific T cell line was subselected from the Rt-BP(d20) line that contained both
the S72-89 and the S87-99 T cell specificities by restimulating the line four times
with only the S87-99 peptide. This subline, designated Rt-BP87-99, lost its response
to the S72-89 peptide of Rt-BP, but retained reactivity to the S87-99 sequence and
to whole Rt-BP (Table VII). The response to S87-99 was inhibited completely by
OX-17, but not OX-6 (Table VII). Thus, unlike any of the BP-specific T cell lines
characterized to date, the Rt-BP87-99 subline was restricted by I-E but not by I-A
MHC class II molecules.
Second, an S87-99 specific T cell line, designated Rt-BP(S87-99), was selected
from the lymph nodes of rats immunized for 12 d with the S87-99 peptide in CFA.
Similar to the Rt-BP87-99 subline described above, the Rt-BP(S87-99) line respond-
ed selectively to the S87-99 peptide and to a lesser degree to Rt-BP, but not to the
44-68 or S72-89 peptides (Table VII). Again, the 87-99 response was restricted
Stimulant
Proliferation
Rt-BP(d9)
response of T cell line :
Rt-BP(d20)
cpm/1, 000
None 2 f 0 6 ± 0
Rt-BP 80 + 6 129 + 10
44-68 2 ± 0 7 f 2
S72-89 81 + 4 57 + 5
+ OX-6 (a I-A) 2 ± 0 (100) 5 ± 1 (100)
+ OX-17 (a I-E) 81 t 3 (0) 52 t 3 (10)
S87-99 2 ± 0 66 ± 8
+ OX-6 (a I-A) ND 62 f 4 (7)
+ OX-17 (a I-E) ND 6 ± 1 (100)o n.w (VHFFK)
a e~-w
0 oaw o n.ta
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TABLE VII
Characterization of Rt-BP S87-99-speck T Cell Lines and Clones
Proliferation response of T cell line/clone:
20,000 T line cells or clones were stimulated for 3 d in the presence of antigens and 106 syngeneic thymic
accessory cells. Proliferation was measured by uptake of ['H]TdR during the last 18 h of culture. mAbs spe-
cific for I-A or I-E were added at the beginning of the culture period to establish MHC class II restriction.
Parentheses indicate percent inhibition.
by I-E but not by I-A (Table VII). Further analysis of the fine specificity indicated
that the Rt-BP(S87-99) line responded equally to the S87-99 and S88-99 peptides,
but had significantly reduced responses to the S90-99 sequence, and virtually no
response to the S91-99 peptide (Fig. 1).
Third, three T cell clones (C-3, C-6, andC10) were isolated from the Rt-BP(87-99)
line using the soft agar technique described previously (8). Each of these clones
responded selectively to the S87-99 peptide, and to a lesser degree to Rt-BP, but
not to the 44-68 or S72-89 peptides (Table VII). Consistent with the Rt-BP87-99
PeptMeconc.laawn (PWMq
FIGURE 1.
￿
Response of the S87-99-specific T cell line to
S87-99 and other synthetic peptides of decreasing length.
2 x 104 T cells were stimulated for 3 d with syngeneic
thymic accessory cells and varyin concentrations ofpep-
tides before an 18-h pulse with [ H]Tdy.
Stimulant Rt-BP87-99 Rt-BP(87-99) Clone C-3 Clone C-6 Clone C-10
None
Rt-BP
4t0
7816
4t0
14t 1
0
cpm/1, 000
0
4t0
0
10t
0
1
1 t0
8t 1
44-68 3t0 4t0 0 0 0 0 1 t0
S72-89 4 t 0 2 t 0 0 0 0 0 1 t 0
S87-99 70 1 6 115 1 3 37 1 2 51 1 4 46 1 2
+ OX-6 (ca I-A) ND 119 t 7 (0) 41 t 1 (0) 48 t 3 (6) 46 t 1 (0)
+ OX-17 (a I-E) ND 42 t 6(66) 1 t 1 (97) 6 t 2 (88) 5 t 1 (89)
PPD 4 1 1 4 1 0 0 1 0 0 1 0 1 1 0362
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and Rt-BP(87-99) lines, the response of all three ofthe S87-99-specific clones was
I-E but not I-A restricted.
Encephalitogenicity ofTCells andBPEpitopesIn Viva
￿
To evaluate encephalitogenic
T cell activity in vivo, we injected 6-10 x 106 activated T cell lines and clones into
naive Lewis rats. As is shown in Table VIII, the GP-BP 44-68-specific Tcells were
unable to induce clinical or histological EAE, although they were capable of trans-
ferringpotent 44-68-specificdelayed hypersensitivity reactions. Bycomparison, the
samenumberofactivatedTcells specific for the 72-89determinant ofGP-BP trans-
ferred both EAE and 72-89-specific DTH responses (Table VIII). Additional ex-
periments (not shown) indicated that rats receiving GP-BP 44-68-specific T cells
were not resistant to a subsequent encephalitogenic challenge with GP-BP in CFA,
nor did the presence ofactivated 44-68-specific T cells within the GP-BP(d28) line
influence in any detectable manner the encephalitogenic activity of72-89-specific
T cells (Table VIII).
In contrast, injection of6-10 x 106 activated Rt-BP87-99 or Rt-BP(S87-99) T line
cells induced clinical and histological EAE in a total of20 of23 recipients, as well
as strong DTH responses(Table VIII). Consistent with the Rt-BP(S87-99) line, the
C-3 and C-6 T cell clones derived from this line also transferred comparable signs
of EAE in three of three recipient rats, as well as strong 87-99-specific DTH re-
sponses (Table VIII).
The encephalitogenic activity demonstrated in the S87-99-specific T cell lines and
clones C-3 andC-6 suggestedthat the S87-99 peptide itselfwouldlikely be encephalito-
genic as well. To evaluate encephalitogenic activity, rats were injected with various
synthetic peptides in CFA. As is shown in Table IX, S87-99, S88-99, and S90-99
peptides all possessed encephalitogenic activity. The S91-99 peptide, which did not
stimulatethe Rt-BP(S87-99) T cell line, however, was only mildly encephalitogenic
(Table IX).
MR.
￿
Previously, we reported that encephalitogenic Tcell lines and clones and
T cell hybridomas specific for the 72-89 peptide ofGP-BP restricted by I-A prefer-
TABLE VIII
Activity of T Cell Lines and Clones In Viao
" Clinical EAE: 0, no signs; 1, limp tail, weight loss; 2, hind leg weakness; 3, hind quarter
paralysis, incontinence.
1 Number positive/total number.
Specificity of Maximum EAE DTH (Amm-2)
T cell line Stimulant severity' 44-68 72-89 87-99
GP-BP(d9) GP-BP 3 .0 ± 0.7 (6/6)1 0 t 0 14 ± 2
GP-BP(d28) GP-BP 3 .2 ± 0.8 (6/6) 7 t 1 15 ± 1
GP-BP44-68 44-68 0 t 0 (0/6) 18 t 2 2 ± 1
GP-BP(44-68) 44-68 0 ± 0 (0/6) 21 t 3 1 ± 1
Rt-BP(d9) Rt-BP 3.5 t 1 .0 (8/8) 11 ± 2 0 t 0
Rt-BP(d28) Rt-BP 2.7 t 0.4 (6/6) 15 t 1 14 ± 2
Rt-BP87-99 87-99 1 .8 ± 0.9 (12/15) 1 ± 1 22 ± 3
Rt-BP(87-99) 87-99 1 .5 t 0.3 (8/8) 3 t 1 24 t 4
Rt-BP clone C-3 87-99 1 .5 t 0.0 (3/3) ND ND
Rt-BP clone C-6 87-99 1 .7 t 0.3 (3/3) ND NDOFFNER ET AL.
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TABLE IX
Induction of EAE with Synthetic Peptidesfrom the 87-99 Region of Rt-BP
` Clinical EAE: 0, no signs; 0.5, lethargy, weight loss; 1, limp tail; 2, hind leg
weakness ; 3, hind quarter paralysis, incontinence.
t Number positive/total number.
TABLE X
TCR V Gene Use
RNA extracted from the T cell lines and clones was blotted onto nitrocellulose
and hybridized with the Va 510 and V# 510 probes as described in Materials
and Methods.
entially used TCRV genesfrom therathomologs ofthemurine Va2 andV08 fami-
lies. Using the same Va and Vii probes, we examined mRNA from the various T
cell lines and clones described above. As expected, the GP-BP-selected T cell line
specific for the 72-89 peptide sequence expressed message for both the Va2 and
the V08 genes (Table X). However, the nonencephalitogenic GP-BP44-68 Tcell line
did not utilize either the Va2 or the V,08 gene.
The encephalitogenic I-E-restricted Rt-BP(S87-99) Tcell line, and the C-3, C-6,
and C-10 clones derived from this line, were all positive forboth the TCR Vcg2 and
V08 genes (Table X) . The presence of both Va2 and V08 message in each of the
clones indicated that these two genes were utilized in combinationin theTCR specific
for the S87-99 peptide restricted by I-E.
Discussion
In this work, we describe for the first time the delayed appearance in immunized
Lewis rats of T cells specific for additional discrete determinants of GP- or Rt-BP.
The secondary GP-BPdeterminant, first detected 14 d afterimmunization, included
the 55-68 sequence and was restricted by I-A. T cells specific for this determinant
T cell line Specificity Restriction
Encepha-
litogenic Va 2 VO 8.2
GP-BP(d9) GP-BP S72-89 I-A + + +
GP-BP(d28) GP-BP 44-68 I-A
GP-BP S72-89 I-A + + +
GP-BP44-68 GP-BP 44-68 I-A
Rt-BP(87-99) Rt-BP S87-99 I-E + + +
Clone C-3 Rt-BP S87-99 I-E + + +
Clone C-6 Rt-BP S87-99 I-E + + +
Clone C-10 Rt-BP S87-99 I-E ND + +
Peptide Dose Maximum clinical EAE"
14g/CFA
Rt-BP S87-99 100 2.0 t 1 .1 (6/6)I
Rt-BP S87-99 100 2.0 t 1 .1 (4/4)
Rt-BP S88-99 100 2.0 t 1 .1 (4/4)
Rt-BP S90-99 100 3.0 t 0.0 (4/4)
Rt-BP S91-99 100 0.5 t 0.0 (4/4)364
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did not respond to the corresponding Rt-BP sequence, which differsby three residues
at positions61-63 (15), andwere not encephalitogenic inspite oftheirabilityto transfer
DTH reactions in vivo.
Further, this study describes a unique encephalitogenic I-E-restricted T cell epi-
tope for Lewis rats located within the 87-99 sequence of Rt-BP. Rat T cell lines
and clones that were responsive to this determinant were able to passively transfer
clinical EAE and specific DTH reactions in vivo, and utilized the same Va2:VO8
gene combinationin their antigenreceptors as T cells specific forthe GP-BPS72-89
determinant restricted by I-A. Immunization of naive rats with peptides as short
as the S90-99 sequence induced active EAE, demonstrating conclusively the en-
cephalitogenicity of this I-E-restricted epitope.
The 87-99 sequence is highly conserved in BP from many species, including Rt,
mouse, GP, and human BP, and it is of great interest that this sequence is also a
major encephalitogenic determinant for the SJL/J(H-25) mouse (5, 17). We demon-
stratedpreviouslythat encephalitogenic SJL/J T cellclones werespecific forthe S87-99
peptide, and were restricted by I-A MHC molecules (17), perhaps due to the ab-
senceoffunctional I-E molecules. Thus, the 87-99determinant ofBP would appear
to be somewhat unusualin its ability toform animmunogenic andencephalitogenic
complex with both rat I-E and mouse I-A restriction molecules. However, unlike
Tcells from rat (Fig. 1), mouse T cells responded fullyto both the S90-99 and S91-99
peptides (17), suggesting differences in fine specificity to this determinant.
The 87-99 sequence of BP, which induced an I-E-restricted T cell response,
representsthe third determinant ofBPcapable ofinducing encephalitogenic T cells
in the Lewis rat. Previous studies have shown that T cells specific for the major en-
cephalitogenic epitope corresponding to the 72-89 sequence ofGP- or Rt-BP were
restricted by I-A(8). Also, avariantT cell specificitydirected at the 72-84 sequence
ofRt-BPwas restricted byI-A (9). Thus, thepresence ofmultiple discrete encephalito-
genic determinants on BP, restricted by either I-A or I-E molecules, demonstrates
clearly the diversity ofthe encephalitogenic process in a given genetic setting, and
supports the notion that both ofthe human homologs ofrodent I-A and I-E mole-
cules, HLA-DQ and HLA-DR, respectively (18), may be capable of participating
inhuman encephalitogenic processes (19). Inthisregard we have observed thatboth
oftheseclass II loci restrict discrete epitopes ofhuman MBP inpatients with neuro-
logic diseases, including multiple sclerosis (19).
Consideringtheputative binding function ofthe TCR with anMHC/peptide com-
plex, the preferential useoftheVa2VO8 gene combinationby twodiscrete encephalito-
genicTcell specificitieswould appear tobe unexpected. To thecontrary, thecurrent
results support our previous unusualfindingthat both B.10/PL mouseT cells specific
fortheBP peptide 1-11 and Lewis rat T cells specific for S72-89 use this same TCR
Va2:VO8 gene combination as well. According to models proposed by Davis and
Bjorkman (20) and Claverie et al. (21), the complementarity determining regions
(CDR) 1 and 2 of the TCR V genes would most likely interact with the MHC re-
striction molecule, whereas the CDR3 region that spans the V-J (a chain) or VDJ
(/3 chain) junction region would most likely interact withthe antigenicpeptidebound
bythe MHC molecule. Basedonthis model, onewould expect TCRsusing the same
Vu:Vo gene combination to recognize the same MHC restriction molecule, and
possibly a portion ofthe same antigenic peptide, depending on selection ofD andOFFNER ET AL.
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J genes andhow much oftheCDR3 region wasassociated with theV gene product.
The T cell specificities described above do not recognize either the same peptide
or the same MHC molecule, and thus suggest interaction of the TCR V gene prod-
ucts with conserved regions of different MHC, or similarities in peptide-binding
properties not discerned from primary sequences.
The appearance ofT cells of a single dominant specificity forthe 72-89 sequence
ofBP is well established in lines selected with wholeGP- or Rt-BP 9 d afterimmuni-
zation (8). As demonstrated in this report,linesselected 14-28 d after immunization
contained T cells of two different specificities, and in the GP-BP selected line, both
specificities were restricted by I-A. During the line selection process, the relative
response to each epitope remained constant, and generally reflected the relative re-
sponse to each epitope observed in the immunized lymph node population (Table
IV). Taken together, these results demonstrate that the process of T cell line selec-
tion did not alter substantially the composition of BP-reactive T cells present ini-
tially in thelymph node. Thus, theemergence ofasingle dominant T cell specificity
in lines selected 9 d after immunization appears to be a reflection of a relatively
high 72-89peptide-specific Tcell frequencyand alow GP-BP 55-68 or Rt-BP 87-99
frequency. In the GP-BP-selected line, where both the 72-89 and 55-68Tcell speci-
ficities persisted, it would appear that competition between the two processed pep-
tides for binding to the available I-A restriction molecules (22, 23) did not play a
significant role in establishing immunodominant T cell specificities.
Summary
The major encephalitogenic epitope forLewis rats is the 72-89 sequence of guinea
pig basic protein (GP-BP) or rat basic protein (Rt-BP). T cells responsive to this
epitope areI-A restricted and preferentially expressthe Va2Yß8 gene combination
in their TCR. In this work, we describe for the first time the delayed appearance
of T cells specific for additional discrete determinant of BP, the nonencephalito-
genic 55-68 sequence of GP-BP restricted by I-A, and the encephalitogenic 87-99
sequence of Rt-BP restricted by I-E. The TCR Va2Yß8 gene combination was
expressed by both encephalitogenic GP-BP S72-89 and Rt-BP S87-99 T cell
specificities but not by GP-BP 44-68-specific T cells. This is the first demonstration
of I-E-restricted encephalitogenic T cells in Lewis rats and supports the conclusion
that the I-E class II locus is involved in autoimmune diseases.
We thank Karin Coffee for help in manuscript preparation.
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